Search

Displaying results 4731 - 4740 of 10000 in total
  1. Drug

    IONIS-FGFR4Rx

    go.drugbank.com/drugs/DB16198
    Investigational

    IONIS-FGFR4Rx is under investigation in clinical trial NCT02476019 (A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients).

  2. Drug

    Ubenimex

    go.drugbank.com/drugs/DB03424
    Investigational

    Ubenimex (also known as bestatin) is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. … It is being studied for use in the treatment of acute myelocytic leukemia.

    Categories: Amino Acids, Peptides, and Proteins
  3. Drug

    LX1031

    go.drugbank.com/drugs/DB05199
    Investigational

    LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders. … LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system

    Categories: Amino Acids, Peptides, and Proteins
  4. Drug

    Hydrocortisone probutate

    go.drugbank.com/drugs/DB14543
    ApprovedVet approved

    Categories: Hydrocortisone and derivatives, Hormones, Hormone Substitutes, and Hormone Antagonists
  5. Drug

    Bordetella pertussis toxoid antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14388
    ApprovedInvestigational

    Bordetella pertussis toxoid antigen (formaldehyde inactivated) is a vaccine.

    Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Repevax Injektionssuspension in einer Fertigspritze
  6. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted. … ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel.

  7. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … [L11106] It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and Pitt Hopkins Syndromes.

    Categories: Amino Acids, Peptides, and Proteins
  8. Drug

    Benzyl alcohol

    go.drugbank.com/drugs/DB06770
    ApprovedInvestigational

    Mixtures: Hand Sanitizer, Fast Freeze Lidocaine Roll-OnCategories: Scabicides, Insecticides and Repellents, Antiparasitic Products, Insecticides and Repellents
  9. Drug

    LX6171

    go.drugbank.com/drugs/DB05180
    Investigational

    LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia

  10. Drug

    Aclidinium

    go.drugbank.com/drugs/DB08897
    Approved

    Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). … It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.

    Categories: formoterol and aclidinium bromide